The Pharma Data

OCTOBER 29, 2021

Novartis blazoned moment that the US Food and Drug Administration (FDA) approved Scemblix ® (asciminib) for the treatment of habitual myeloid leukemia (CML) in two distinct suggestions. Scemblix is the first FDA-approved CML treatment that binds to the ABL myristoyl pocket1. Bosulif ® (bosutinib) * at 24 weeks (25vs.

FDA Approval 52

FDA Approval FDA Treatment Trials 52

The Pharma Data

OCTOBER 22, 2020

FDA Approves Veklury (remdesivir) for the Treatment of COVID-19. Food and Drug Administration (FDA) has approved the antiviral drug Veklury (remdesivir) for the treatment of patients with COVID-19 requiring hospitalization. The speed and rigor with which Veklury has been developed and approved in the U.S.

FDA Approval 52

FDA Approval Treatment FDA Hospitals 52

The Pharma Data

JUNE 7, 2023

FDA Approves New Indication for Merck’s PREVYMIS® (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Source link: [link]

FDA Approval 40

FDA Approval FDA Disease Research Laboratories 40

The Pharma Data

NOVEMBER 20, 2020

FDA Approves Zokinvy (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies. LABORATORY ABNORMALITIES. Some patients treated with ZOKINVY developed laboratory abnormalities. Related Articles: Zokinvy (lonafarnib) FDA Approval History. PALO ALTO, Calif.,

FDA Approval 52

FDA Approval FDA Clinical Trials Disease 52

The Pharma Data

JANUARY 20, 2021

FDA Approves Verquvo (vericiguat) for Heart Failure with Reduced Ejection Fraction. This approval builds upon Merck’s proud history of developing therapies for the treatment of patients with cardiovascular disease.”. Related Articles: Verquvo (vericiguat) FDA Approval History. KENILWORTH, N.J.–(BUSINESS

FDA Approval 52

FDA Approval FDA Hospitals Treatment 52

The Pharma Data

AUGUST 24, 2020

The treatment is being researched by scientists collaborating from American Gene Technologies, the Laboratory of Immunoregulation and the National Institute of Allergy and Infectious Diseases.

FDA Approval 52

FDA Approval Therapies FDA Trials 52

Drug Discovery World

JULY 2, 2024

Superlab Suisse, a provider of laboratory and research spaces, is a great example of this mix of regionality and reproducibility. This also means there is no shortage of skilled workers thanks to the universities and the well-established apprenticeship system, for example, in the field of biology laboratory technicians.

Science 147

Science Drugs Clinical Trials Licensing 147

Drug Discovery World

MARCH 16, 2023

With a maturing clinical pipeline, many FDA-approved treatments are on the horizon. The cell and gene therapy (CGT) market is rapidly expanding, and projections suggest it will reach over $90B by 2023.

Therapies 130

Therapies FDA Approval Science Production 130

The Pharma Data

DECEMBER 18, 2020

FDA Approves Orgovyx (relugolix) as the First Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer. Food and Drug Administration (FDA) has approved Orgovyx (relugolix) for the treatment of adult patients with advanced prostate cancer. Most common laboratory abnormalities (?

FDA Approval 52

FDA Approval FDA Science Therapies 52

Drug Discovery World

APRIL 23, 2024

Although not a test to diagnose concussion, a biomarker test developed by Abbott Laboratories helps to determine whether a patient should receive a CT scan to rule out haemorrhage. Tremendous strides have been made with other diseases, yet there are still no FDA-approved drug therapies for TBI.

Therapies 147

Therapies Drugs Laboratories Medical Schools 147

Drug Discovery World

APRIL 10, 2024

The post FDA approves first in vivo gene insertion programme in infants appeared first on Drug Discovery World (DDW). The ECUR-506 programme represents the first time that the ARCUS nuclease has been used to provide an in vivo insertion point for a functional gene in the clinic.

FDA Approval 200

FDA Approval FDA Pharmacokinetics Laboratories 200

ASPET

JANUARY 31, 2024

Unfortunately, GBM has a ~100% recurrence rate, but after recurrence there are no FDA-approved therapies to limit tumor growth and enhance patient survival, as these tumors are resistant to TMZ.

Therapies 40

Therapies FDA Approval Laboratories Treatment 40

The Premier Consulting Blog

APRIL 15, 2024

We will use the term, nonclinical, to refer to any in vitro, ex vivo, or animal study conducted to support any stage of research and development of a new drug, such as proof-of-concept pharmacology studies through Good Laboratory Practice (GLP) toxicology studies. neurotoxicity) that require special assessments.

FDA 52

FDA Pharmacokinetics Laboratories FDA Approval 52

ASPET

JULY 20, 2023

Nitrogen mustard (NM), a bifunctional alkylating agent and potent analog of SM, is used in laboratories to study mustard vesicant-induced ocular toxicity. Previously, we showed that SM-/NM-induced injuries ( in vivo and ex vivo rabbit corneas) are reversed upon dexamethasone (DEX) treatment, an FDA approved, steroidal anti-inflammatory drug.

FDA Approval 40

FDA Approval Laboratories FDA Treatment 40

The Pharma Data

DECEMBER 16, 2020

Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.

FDA Approval 52

FDA Approval Laboratories Pharmaceuticals Disease 52

The Pharma Data

JANUARY 19, 2021

Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.

FDA Approval 52

FDA Approval Laboratories Pharmaceuticals Disease 52

The Pharma Data

NOVEMBER 30, 2020

Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.

FDA Approval 52

FDA Approval Laboratories Pharmaceuticals Disease 52

The Pharma Data

OCTOBER 27, 2020

Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.

FDA Approval 52

FDA Approval Laboratories Pharmaceuticals Disease 52

The Pharma Data

FEBRUARY 23, 2022

For laboratory workers: TBE vaccination is recommended for those with a potential exposure to the TBE virus (TBEV). Food and Drug Administration (FDA) approved TicoVac™ for active immunization to prevent TBE in individuals 1 year of age and older. 1 TicoVac™ is the only FDA-approved vaccine to help protect U.S.

Vaccine 52

Vaccine FDA Approval Laboratories Virus 52

The Pharma Data

AUGUST 17, 2021

Second FDA approved indication for dostarlimab in 2021 GARNET study demonstrated objective response rate of 41.6% This indication received accelerated approval based on tumour response rate and durability of response. Grade 3 or 4 laboratory abnormalities (?2%) The most common Grade 3 or 4 laboratory abnormalities (?2%)

FDA 52

FDA FDA Approval DNA Treatment 52

The Pharma Data

NOVEMBER 20, 2020

The EUA for the combination treatment applies to hospitalized patients ages 2 years and older with suspected or laboratory-confirmed COVID-19 who require supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation.

FDA 52

FDA FDA Approval Hospitals Clinical Trials 52

The Pharma Data

SEPTEMBER 7, 2021

Because of its selectivity for oxycodone, the vaccine will not interfere with FDA-approved medications, including methadone, buprenorphine, naltrexone and naloxone, potentially offering a long-lasting, safe and cost-effective alternative that is complementary to standard medical intervention for opioid use disorders.

Clinical Trials 52

Clinical Trials Vaccine Trials Medical Schools 52

Advarra

JULY 5, 2022

The results of glucose monitoring with a continuous glucose monitor (GCM) already approved by the Food and Drug Administration (FDA) is an example of a validated result. Conversely, a CGM not yet FDA-approved assessed in the study for reliability, would yield an investigational result.

Research 97

Research FDA Approval Packaging FDA 97

The Pharma Data

DECEMBER 15, 2020

” Last week, the FDA approved a different at-home test, but it requires samples to be mailed to a lab to get the results. The new Ellume COVID-19 Home Test approved Tuesday detects SARS-CoV-2 virus protein fragments on nasal swab samples from any person 2 years of age or older, according to the FDA. .

FDA 52

FDA FDA Approval Doctors Laboratories 52

The Pharma Data

APRIL 28, 2023

Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC), by a vote of 11 to 1 with one abstention, supported FDA approval of LYNPARZA plus abiraterone and prednisone or prednisolone (abi/pred) for the first-line treatment of adult patients with BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC).

FDA 40

FDA FDA Approval Trials Treatment 40

Drug Discovery World

APRIL 27, 2023

Research spotlight : In February 2023, Duke University co-investigators took a groundbreaking step in the treatment of geographic atrophy (GA), an advanced form of dry macular degeneration through the FDA approval of pegcetacoplan, the first ever FDA-approved treatment for GA.

Small Molecule 130

Small Molecule Science Drugs FDA Approval 130

The Pharma Data

JULY 18, 2021

Food and Drug Administration (FDA) approved VAXNEUVANCE ™ (Pneumococcal 15-valent Conjugate Vaccine) (pronounced VAKS-noo-vans) for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in adults 18 years of age and older.

Disease 52

Disease Immune Response Vaccine FDA Approval 52

The Pharma Data

OCTOBER 26, 2020

FDA Actions. FDA Approval: Last week the FDA approved Veklury (remdesivir) for the treatment of COVID-19 requiring hospitalization in adults and pediatric patients (12 years of age and older). News information is not all-inclusive and updates are published once a week on Tuesdays. . .

Vaccine 52

Vaccine FDA Approval FDA Clinical Trials 52

The Pharma Data

AUGUST 3, 2021

Abnormal Laboratory Values: There is limited information regarding use of baricitinib in patients with COVID-19 and any of the following clinical findings: absolute neutrophil count (ANC) <1000 cells/mm 3 , absolute lymphocyte count (ALC) <200 cells/mm 3 , and hemoglobin <8 g/dL. It is approved in the U.S.

Hospitals 52

Hospitals Licensing Licensing FDA Approval 52

The Pharma Data

JULY 29, 2021

Essential safety information on the authorized emergency use of baricitinib includes warnings related to serious infections, thrombosis, abnormal laboratory values, vaccinations and hypersensitivity. Monitor closely when treating patients with abnormal baseline and post-baseline laboratory values. It is approved in the U.S.

Hospitals 52

Hospitals FDA Laboratories Licensing 52

PerkinElmer

APRIL 21, 2020

Using the isolated ZIKV MEX_I_7 strain, researchers got a head start on potential leads by interrogating a library of existing, FDA-approved drugs that can be used off-label for treatment of Zika. High-content imaging was used in a recent study aiming to identify novel ZIKV inhibitors from a pool of 774 compounds.

Virus 52

Virus FDA Approval Laboratories Vaccine 52

The Pharma Data

NOVEMBER 16, 2020

Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.

FDA Approval 52

FDA Approval Science Disease Laboratories 52

FDA Law Blog: Biosimilars

JULY 5, 2023

As a reminder, in Title I of the 2013 Drug Quality and Security Act (DQSA) (the Compounding Quality Act), Congress created the “outsourcing facility” FDA registration category, and set forth statutory parameters for their operation in new section 503B of the FDCA. See 21 U.S.C. Section II at 2.

FDA 52

FDA FDA Approval Licensing Licensing 52

The Pharma Data

MAY 4, 2021

Abnormal Laboratory Values: Evaluate at baseline and thereafter according to local patient management practice. Monitor closely when treating patients with abnormal baseline and post-baseline laboratory values. Manage patients according to routine clinical guidelines. patients with a history of diverticulitis).

Licensing 40

Licensing Licensing Therapies Laboratories 40

Broad Institute

APRIL 25, 2024

Hospitals with laboratories use pathogen detection technology developed by Sabeti’s group that scans samples for a panel of additional pathogens. Sentinel is also developing a SHINE test to detect Lassa virus in rural clinics in Nigeria, where there are currently no FDA-approved diagnostics for the disease.

Virus 132

Virus Hospitals Disease Government 132

The Pharma Data

OCTOBER 22, 2020

With today’s FDA approval, and regulatory approvals or temporary authorizations in approximately 50 additional countries around the world, Veklury® (remdesivir) is one of the tools available today. [ii] Perform hepatic laboratory testing in all patients (see Dosage and administration). Adverse reactions.

Science 52

Science Clinical Trials Hospitals FDA Approval 52

The Pharma Data

AUGUST 19, 2021

Food and Drug Administration (FDA) approval for patients with locally advanced or metastatic NSCLC with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, based on data showing an ORR of 40 percent (95 percent CI, 29 – 51) and median duration of response of 11.1 The most common Grade 3 or 4 laboratory abnormalities (?2%)

Treatment 52

Treatment FDA Approval Pharmacokinetics FDA 52